Theratechnologies Inc T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:My opinion

[qwerty22]

On a brighter note. Cancer deal.

"With a re­cent ap­proval for lung can­cer bis­pe­cif­ic ami­van­tam­ab, J&J is look­ing to build a fran­chise in that space with a grow­ing crop of drugs in the pipeline. The drug gi­ant has now tapped a fa­mil­iar part­ner to dri­ve that work ahead, and the pair is go­ing af­ter a well-known tar­get.

J&J's Janssen unit has inked a li­cens­ing deal worth $100 mil­lion in up­front cash and $25 mil­lion in eq­ui­ty for glob­al li­cens­ing rights to Xen­cor's CD20/CD3 bis­pe­cif­ic an­ti­body plam­o­tam­ab cur­rent­ly in Phase I test­ing against B cell ma­lig­nan­cies, the com­pa­nies said Mon­day.

The deal will come with up to $1.18 bil­lion in down­stream mile­stones as well as po­ten­tial roy­al­ties in the "mid-teens to low twen­ties," ac­cord­ing to a re­lease.

Janssen will hold ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights world­wide for plam­o­tam­ab, in­clud­ing in monother­a­py and com­bo reg­i­mens, with Xen­cor and Janssen split­ting fu­ture clin­i­cal tri­al costs 20-80, re­spec­tive­ly. Those plans in­clude a sub­cu­ta­neous for­mu­la­tion tri­al for the bis­pe­cif­ic, which is ex­pect­ed to be­gin in 2022. Mean­while, Xen­cor will ex­clu­sive­ly fund a Phase II com­bo study of plam­o­tam­ab, taf­a­sita­m­ab and lenalido­mide in pa­tients with B-cell lym­phoma set to start in late 2021 or ear­ly 2022.

The col­lab­o­ra­tion will al­so fu­el R&D for new CD28-tar­get­ing bis­pecifics out of Xen­cor's pipeline, with the part­ners col­lab­o­rat­ing on a two-year re­search project. Janssen will hold an ex­clu­sive world­wide li­cense to de­vel­op any se­lect­ed mol­e­cules that come out of that work as part of a com­bo with plam­o­tam­ab or oth­er an­ti­bod­ies, in­clud­ing those tar­get­ing CD3, where they would com­pete di­rect­ly with Re­gen­eron."